دورية أكاديمية
أعرض في EDS

Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.

التفاصيل البيبلوغرافية
العنوان: Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
المؤلفون: Garman B; Translational Medicine, Bristol Myers Squibb, Lawrenceville, NJ, United States., Jiang C; Translational Medicine, Bristol Myers Squibb, Lawrenceville, NJ, United States., Daouti S; Translational Medicine, Bristol Myers Squibb, Lawrenceville, NJ, United States., Kumar S; Translational Medicine, Bristol Myers Squibb, Lawrenceville, NJ, United States., Mehta P; Translational Medicine, Bristol Myers Squibb, Lawrenceville, NJ, United States., Jacques MK; Translational Medicine, Bristol Myers Squibb, Lawrenceville, NJ, United States., Menard L; Translational Medicine, Bristol Myers Squibb, Lawrenceville, NJ, United States., Manjarrez-Orduno N; Translational Medicine, Bristol Myers Squibb, Lawrenceville, NJ, United States., Dolfi S; Translational Medicine, Bristol Myers Squibb, Lawrenceville, NJ, United States., Mukherjee P; Translational Medicine, Bristol Myers Squibb, Lawrenceville, NJ, United States.; Epigenomics Core Facility, Weill Cornell Medicine, New York City, NY, United States., Rai SC; Translational Medicine, Bristol Myers Squibb, Lawrenceville, NJ, United States., Lako A; Translational Medicine, Bristol Myers Squibb, Lawrenceville, NJ, United States., Koenitzer JD; Translational Medicine, Bristol Myers Squibb, Lawrenceville, NJ, United States., David JM; Translational Medicine, Bristol Myers Squibb, Lawrenceville, NJ, United States.
المصدر: Frontiers in immunology [Front Immunol] 2023 Sep 19; Vol. 14, pp. 1151748. Date of Electronic Publication: 2023 Sep 19 (Print Publication: 2023).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: Programmed Cell Death 1 Receptor*/metabolism , Melanoma*, Humans ; CTLA-4 Antigen ; Leukocytes, Mononuclear ; Immunophenotyping ; Ligands ; Tumor Microenvironment ; Fibrinogen/therapeutic use
مستخلص: Background: Immune cell expression profiling from patient samples is critical for the successful development of immuno-oncology agents and is useful to understand mechanism-of-action, to identify exploratory biomarkers predictive of response, and to guide treatment selection and combination therapy strategies. LAG-3 is an inhibitory immune checkpoint that can suppress antitumor T-cell responses and targeting LAG-3, in combination with PD-1, is a rational approach to enhance antitumor immunity that has recently demonstrated clinical success. Here, we sought to identify human immune cell subsets that express LAG-3 and its ligands, to characterize the marker expression profile of these subsets, and to investigate the potential relationship between LAG-3 expressing subsets and clinical outcomes to immuno-oncology therapies.
Methods: Comprehensive high-parameter immunophenotyping was performed using mass and flow cytometry of tumor-infiltrating lymphocytes (TILs) and peripheral blood mononuclear cells (PBMCs) from two independent cohorts of samples from patients with various solid tumor types. Profiling of circulating immune cells by single cell RNA-seq was conducted on samples from a clinical trial cohort of melanoma patients treated with immunotherapy.
Results: LAG-3 was most highly expressed by subsets of tumor-infiltrating CD8 T central memory (TCM) and effector memory (TEM) cells and was frequently co-expressed with PD-1. We determined that these PD-1 + LAG-3 + CD8 memory T cells exhibited a unique marker profile, with greater expression of activation (CD69, HLA-DR), inhibitory (TIM-3, TIGIT, CTLA-4) and stimulatory (4-1BB, ICOS) markers compared to cells that expressed only PD-1 or LAG-3, or that were negative for both checkpoints. In contrast to tumors, LAG-3 expression was more limited in circulating immune cells from healthy donors and solid tumor patients. Additionally, we found abundant expression of the LAG-3 ligands MHC-II and galectin-3 in diverse immune cell types, whereas FGL1 and LSECtin were minimally expressed by immune cells in the tumor microenvironment (TME). Lastly, we found an inverse relationship between baseline and on-treatment levels of circulating LAG3 transcript-expressing CD8 memory T cells and response to combination PD-1 and CTLA-4 blockade in a clinical trial cohort of melanoma patients profiled by scRNAseq.
Conclusions: These results provide insights into the nature of LAG-3- and ligand-expressing immune cells within the TME, and suggest a biological basis for informing mechanistic hypotheses, treatment selection strategies, and combination immunotherapy approaches to support continued development of dual PD-1 and LAG-3 blockade.
Competing Interests: Authors BG, CJ, SDa, SK, PMe, MJ, LM, NM-O, SDo, SR, AL, JK, and JD were employed by the company Bristol Myers Squibb. Author PMu is a contingent worker and consultant providing services to Bristol Myers Squibb. The authors declare that this work was funded entirely by Bristol Myers Squibb. The funder had the following involvement with the study: study design, data collection and analysis, decision to publish, and preparation of the manuscript.
(Copyright © 2023 Garman, Jiang, Daouti, Kumar, Mehta, Jacques, Menard, Manjarrez-Orduno, Dolfi, Mukherjee, Rai, Lako, Koenitzer and David.)
References: Nature. 2018 Jun;558(7710):454-459. (PMID: 29899446)
J Exp Med. 2017 Feb;214(2):381-400. (PMID: 28115575)
Front Immunol. 2018 Dec 18;9:2981. (PMID: 30619337)
Front Immunol. 2015 Aug 21;6:418. (PMID: 26347741)
J Exp Med. 1998 Dec 21;188(12):2205-13. (PMID: 9858507)
Oncotarget. 2015 Sep 29;6(29):27359-77. (PMID: 26318293)
Nat Biotechnol. 2018 Jun;36(5):411-420. (PMID: 29608179)
Cancer Immunol Res. 2022 Oct 4;10(10):1175-1189. (PMID: 35981087)
J Exp Med. 1998 May 4;187(9):1383-93. (PMID: 9565631)
Nat Immunol. 2022 May;23(5):757-767. (PMID: 35437325)
J Invest Dermatol. 2014 Jul;134(7):1893-1902. (PMID: 24441096)
Cell. 2017 Feb 9;168(4):707-723. (PMID: 28187290)
N Engl J Med. 2022 Jan 6;386(1):24-34. (PMID: 34986285)
Bioinformatics. 2016 Aug 15;32(16):2473-80. (PMID: 27153628)
Nature. 2019 Jul;571(7764):270-274. (PMID: 31207604)
Sci Immunol. 2020 Jul 17;5(49):. (PMID: 32680952)
Immunity. 2022 May 10;55(5):912-924.e8. (PMID: 35413245)
Clin Cancer Res. 2019 Aug 1;25(15):4663-4673. (PMID: 31053602)
Immunol Lett. 2013 Feb;150(1-2):116-22. (PMID: 23261718)
Semin Immunol. 2019 Apr;42:101305. (PMID: 31604537)
Clin Cancer Res. 2022 Nov 14;28(22):4893-4906. (PMID: 35852792)
J Immunol. 1998 Oct 15;161(8):4058-65. (PMID: 9780176)
Cancer Res. 2014 Jul 1;74(13):3418-28. (PMID: 24769443)
Clin Cancer Res. 2017 Apr 15;23(8):1929-1936. (PMID: 27756788)
Nat Methods. 2019 Dec;16(12):1289-1296. (PMID: 31740819)
Nat Commun. 2018 Jul 13;9(1):2724. (PMID: 30006565)
Cell. 2021 Jun 24;184(13):3573-3587.e29. (PMID: 34062119)
Nat Commun. 2019 Nov 28;10(1):5415. (PMID: 31780669)
J Clin Invest. 2011 Jun;121(6):2350-60. (PMID: 21555851)
Sci Transl Med. 2021 Aug 25;13(608):. (PMID: 34433638)
J Clin Invest. 2014 May;124(5):2246-59. (PMID: 24667641)
Lancet Oncol. 2016 Nov;17(11):1558-1568. (PMID: 27622997)
Nat Cancer. 2022 Sep;3(9):1123-1136. (PMID: 36138134)
J Immunother Cancer. 2020 Dec;8(2):. (PMID: 33335029)
J Immunol. 2004 Dec 1;173(11):6806-12. (PMID: 15557174)
Nat Immunol. 2018 Dec;19(12):1415-1426. (PMID: 30349037)
N Engl J Med. 2015 May 21;372(21):2006-17. (PMID: 25891304)
Cancer Immunol Res. 2015 Apr;3(4):412-23. (PMID: 25691328)
J Immunol. 2020 Aug 1;205(3):864-871. (PMID: 32591399)
Cytometry A. 2015 Jul;87(7):636-45. (PMID: 25573116)
Nat Med. 2018 Jul;24(7):994-1004. (PMID: 29892065)
Nat Rev Immunol. 2015 Aug;15(8):486-99. (PMID: 26205583)
Nat Rev Cancer. 2020 Apr;20(4):218-232. (PMID: 32024970)
Nature. 2019 Jul;571(7764):211-218. (PMID: 31207603)
Genes Cancer. 2018 May;9(5-6):176-189. (PMID: 30603054)
Immunity. 2020 May 19;52(5):825-841.e8. (PMID: 32396847)
Cancer Res. 2012 Feb 15;72(4):917-27. (PMID: 22186141)
Cell. 2019 Jun 13;177(7):1888-1902.e21. (PMID: 31178118)
J Immunol. 2004 May 1;172(9):5450-5. (PMID: 15100286)
Front Immunol. 2018 Feb 27;9:385. (PMID: 29535740)
Science. 2012 Nov 30;338(6111):1220-5. (PMID: 23197535)
Front Immunol. 2018 Nov 26;9:2728. (PMID: 30534127)
Clin Cancer Res. 2014 Jan 1;20(1):44-55. (PMID: 24045181)
J Clin Invest. 2019 Jun 18;129(9):3770-3785. (PMID: 31211698)
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80. (PMID: 20385810)
PLoS Pathog. 2014 Jul 17;10(7):e1004251. (PMID: 25032686)
Nat Rev Immunol. 2022 Apr;22(4):209-223. (PMID: 34253904)
Mol Cells. 2000 Apr 30;10(2):119-26. (PMID: 10850651)
Cell. 2019 Jan 10;176(1-2):334-347.e12. (PMID: 30580966)
Nat Biotechnol. 2015 May;33(5):495-502. (PMID: 25867923)
فهرسة مساهمة: Keywords: CD8 memory T cell; Immunophenotyping; Immunotherapy; LAG-3; MHC-II; PD-1; TIL; galectin-3
المشرفين على المادة: 0 (CTLA-4 Antigen)
0 (Programmed Cell Death 1 Receptor)
0 (Ligands)
0 (FGL1 protein, human)
9001-32-5 (Fibrinogen)
تواريخ الأحداث: Date Created: 20231005 Date Completed: 20231101 Latest Revision: 20231102
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10546411
DOI: 10.3389/fimmu.2023.1151748
PMID: 37795090
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2023.1151748